Plasma cyclic AMP response to XXXX : a potential clinical marker of bone turnover.

@entity1 @entity3747 @entity175 @entity268 @entity604 @entity460 @entity35 @entity2742
A noninvasive marker of bone turnover would be useful in predicting which @entity1 are at risk of rapid @entity604 and in monitoring response to therapy. @entity175 (CT)-induced @entity3747 correlates with bone turnover but has not been a clinically useful test because changes in serum @entity460 are small, and test duration is long. CT rapidly increases plasma @entity268 levels. We conducted studies in @entity35 and in @entity1 to characterize the origin of this rise, and to determine its suitability as a potential clinical marker of bone resorption. Administration of CT to @entity35 resulted in a prompt and sustained rise in plasma @entity268 . This effect was not blunted by nephrectomy and was greater in @entity460 -deprived @entity35 with increased bone resorption. Thus, it appears to reflect CT action on bone. An intramuscular injection of 100 units salmon CT elevated plasma @entity268 in 18 normal @entity1 and @entity1 . This effect was observed by 20 min after injection and persisted over 2 h. Although basal levels of plasma @entity268 were similar in healthy postmenopausal @entity1 and @entity1 , the response to CT was greater in @entity1 . The response of @entity1 with @entity2742 was greater than that of normal @entity1 , and the response of pagetic @entity1 was greater than that of normal @entity1 . The rise in plasma @entity268 following CT is rapid and easily measured and appears to correlate with the state of bone remodeling. Additional studies will be required in osteoporotic subjects with high and low remodeling activity before the clinical utility of this test can be determined.
